TCA108

TCA108 is an investigational pharmaceutical drug undergoing Phase 3 clinical development for the treatment of uncontrolled hypertension in adults. It is being evaluated as a once-daily oral tablet intended to lower blood pressure in patients whose hypertension is not adequately controlled by standard therapies. The mechanism of action and precise drug class have not been disclosed in publicly available information as of July 2025, but it is developed specifically for cardiovascular indications, with its main focus on reducing systolic and diastolic blood pressure measured over an 8-week period. The Phase 3 trial is designed as a randomized, double-blind, parallel-group comparison against Bramicar HCT, a currently available antihypertensive. The lead sponsor and initial developer is EMS, a major pharmaceutical company based in Brazil[2][4][6][9].

Brand names

TCA108TCA-108TCA 108

Other names

TCA108TCA-108TCA 108